Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IG-004
- Development stage
- Unknown
- Lead developer
- Sorrento Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
**IG-004 (TOCOSOL® paclitaxel)** is a nanomedicine formulation of the chemotherapy agent paclitaxel, utilizing a tocopheryl polyethylene glycol succinate (TPGS)-based emulsion to enhance solubility and delivery without Cremophor EL, potentially reducing hypersensitivity reactions associated with standard paclitaxel. It acts as a microtubule stabilizer, inhibiting cell division in rapidly proliferating cancer cells. Developed through a collaboration between Sorrento Therapeutics and IGDRASOL, IG-004 has advanced to late-stage clinical testing, completing Phase 2 or 3 trials for metastatic breast cancer (MBC).[3]
- Brand names
- TOCOSOL paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on IG-004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IG-004.